Literature DB >> 26311882

Host Gene Expression Is Regulated by Two Types of Noncoding RNAs Transcribed from the Epstein-Barr Virus BamHI A Rightward Transcript Region.

Aron R Marquitz1, Anuja Mathur1, Rachel Hood Edwards1, Nancy Raab-Traub2.   

Abstract

UNLABELLED: In Epstein-Barr virus-infected epithelial cancers, the alternatively spliced BamHI A rightward transcripts (BARTs) are the most abundant viral polyadenylated RNA. The BART introns form the template for the production of 44 microRNAs (miRNAs), and the spliced and polyadenylated exons form nuclear non-protein-coding RNAs. Analysis of host cell transcription by RNA-seq during latency in AGS cells identified a large number of reproducibly changed genes. Genes that were downregulated were enriched for BART miRNA targets. Bioinformatics analysis predicted activation of the myc pathway and downregulation of XBP1 as likely mediators of the host transcriptional changes. Effects on XBP1 activity were not detected in these cells; however, myc activation was confirmed through use of a myc-responsive luciferase reporter. To identify potential regulatory properties of the spliced, polyadenylated BART RNAs, a full-length cDNA clone of one of the BART isoforms was obtained and expressed in the Epstein-Barr virus (EBV)-negative AGS cells. The BART cDNA transcript remained primarily nuclear yet induced considerable and consistent changes in cellular transcription, as profiled by RNA-seq. These transcriptional changes significantly overlapped the transcriptional changes induced during latent EBV infection of these same cells, where the BARTs are exclusively nuclear and do not encode proteins. These data suggest that the nuclear BART RNAs are functional long noncoding RNAs (lncRNAs). The abundant expression of multiple forms of noncoding RNAs that contribute to growth regulation without expression of immunogenic proteins would be an important mechanism for viral oncogenesis in the presence of a functional immune system. IMPORTANCE: Infection with Epstein-Barr virus (EBV) is nearly ubiquitous in the human population; however, it does contribute to the formation of multiple types of cancer. In immunocompromised patients, EBV causes multiple types of lymphomas by expressing viral oncogenes that promote growth and survival of infected B lymphocytes. EBV-positive gastric carcinoma does not require immune suppression, and the viral oncoproteins that are frequent targets for an immunological response are not expressed. This study demonstrates using transcriptional analysis that the expression of various classes of viral non-protein-coding RNAs likely contribute to the considerable changes in the host transcriptional profile in the AGS gastric cancer cell line. This is the first report to show that the highly expressed polyadenylated BamHI A rightward transcripts (BART) viral transcript in gastric carcinoma is in fact a functional viral long noncoding RNA. These studies provide new insight into how EBV can promote transformation in the absence of viral protein expression.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26311882      PMCID: PMC4645673          DOI: 10.1128/JVI.01492-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

2.  The Epstein-Barr virus encoded BART miRNAs potentiate tumor growth in vivo.

Authors:  Jin Qiu; Pamela Smith; Leah Leahy; David A Thorley-Lawson
Journal:  PLoS Pathog       Date:  2015-01-15       Impact factor: 6.823

Review 3.  The role of miRNAs and EBV BARTs in NPC.

Authors:  Aron R Marquitz; Nancy Raab-Traub
Journal:  Semin Cancer Biol       Date:  2011-12-10       Impact factor: 15.707

4.  let-7 microRNA functions as a potential growth suppressor in human colon cancer cells.

Authors:  Yukihiro Akao; Yoshihito Nakagawa; Tomoki Naoe
Journal:  Biol Pharm Bull       Date:  2006-05       Impact factor: 2.233

Review 5.  Long noncoding RNAs: cellular address codes in development and disease.

Authors:  Pedro J Batista; Howard Y Chang
Journal:  Cell       Date:  2013-03-14       Impact factor: 41.582

6.  DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative.

Authors:  N Raab-Traub; T Dambaugh; E Kieff
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

7.  Epstein-Barr virus transcription in nasopharyngeal carcinoma.

Authors:  N Raab-Traub; R Hood; C S Yang; B Henry; J S Pagano
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

8.  Identification of Epstein-Barr virus RK-BARF0-interacting proteins and characterization of expression pattern.

Authors:  Natalie J Thornburg; Shuichi Kusano; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 9.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

10.  EBV BART MicroRNAs Target Multiple Pro-apoptotic Cellular Genes to Promote Epithelial Cell Survival.

Authors:  Dong Kang; Rebecca L Skalsky; Bryan R Cullen
Journal:  PLoS Pathog       Date:  2015-06-12       Impact factor: 6.823

View more
  30 in total

Review 1.  Long non-coding RNAs in nasopharyngeal carcinoma: biological functions and clinical applications.

Authors:  Yao Tang; Xiusheng He
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.396

2.  Expression of pseudorabies virus-encoded long noncoding RNAs in epithelial cells and neurons.

Authors:  Xiang Guan; Jie Liu; Hui Jiang; Chang-Xian Wu; Huan-Chun Chen; Zheng-Fei Liu
Journal:  J Neurovirol       Date:  2018-07-09       Impact factor: 2.643

3.  Downregulation of the Long Noncoding RNA IALNCR Targeting MAPK8/JNK1 Promotes Apoptosis and Antagonizes Bovine Viral Diarrhea Virus Replication in Host Cells.

Authors:  Xuwen Gao; Xiaobo Sun; Xin Yao; Yixin Wang; Yuan Li; Xiaoxia Jiang; Yanyan Han; Linhan Zhong; Li Wang; Houhui Song; Yigang Xu
Journal:  J Virol       Date:  2022-08-22       Impact factor: 6.549

Review 4.  Epstein-Barr virus: Biology and clinical disease.

Authors:  Blossom Damania; Shannon C Kenney; Nancy Raab-Traub
Journal:  Cell       Date:  2022-09-15       Impact factor: 66.850

Review 5.  Connivance, Complicity, or Collusion? The Role of Noncoding RNAs in Promoting Gammaherpesvirus Tumorigenesis.

Authors:  Whitney L Bullard; Erik K Flemington; Rolf Renne; Scott A Tibbetts
Journal:  Trends Cancer       Date:  2018-10-10

6.  A Genome-Wide Epstein-Barr Virus Polyadenylation Map and Its Antisense RNA to EBNA.

Authors:  Vladimir Majerciak; Wenjing Yang; Jing Zheng; Jun Zhu; Zhi-Ming Zheng
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 7.  Thirty years of Epstein-Barr virus-associated gastric carcinoma.

Authors:  Masashi Fukayama; Hiroyuki Abe; Akiko Kunita; Aya Shinozaki-Ushiku; Keisuke Matsusaka; Tetsuo Ushiku; Atsushi Kaneda
Journal:  Virchows Arch       Date:  2019-12-13       Impact factor: 4.064

Review 8.  Viral non-coding RNAs: Stealth strategies in the tug-of-war between humans and herpesviruses.

Authors:  Takanobu Tagawa; Anna Serquiña; Insun Kook; Joseph Ziegelbauer
Journal:  Semin Cell Dev Biol       Date:  2020-07-03       Impact factor: 7.727

9.  Major Role for Cellular MicroRNAs, Long Noncoding RNAs (lncRNAs), and the Epstein-Barr Virus-Encoded BART lncRNA during Tumor Growth In Vivo.

Authors:  Rachel Hood Edwards; Nancy Raab-Traub
Journal:  mBio       Date:  2022-04-18       Impact factor: 7.786

Review 10.  Pathogenic Role of Epstein-Barr Virus in Lung Cancers.

Authors:  David Becnel; Ramsy Abdelghani; Asuka Nanbo; Janardhan Avilala; Jacob Kahn; Li Li; Zhen Lin
Journal:  Viruses       Date:  2021-05-11       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.